Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss

2018350 citationsJournal Articlebronze Open Access

Authors

Penelope Brock · Great Ormond Street Hospital

Rudolf Maibach · International Breast Cancer Study Group

Margaret Childs

Kaukab Rajput · University College London

Derek Roebuck · Great Ormond Street Hospital

Michael Sullivan · University of Otago

Véronique Laithier · Centre Hospitalier Universitaire de Besançon

Abstract

The addition of sodium thiosulfate, administered 6 hours after cisplatin chemotherapy, resulted in a lower incidence of cisplatin-induced hearing loss among children with standard-risk hepatoblastoma, without jeopardizing overall or event-free survival. (Funded by Cancer Research UK and others; SIOPEL 6 ClinicalTrials.gov number, NCT00652132 ; EudraCT number, 2007-002402-21 .).

Topics & Keywords

Ear and Head Tumors Brain Metastases and Treatment Lung Cancer Research Studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 378, Issue 25, pp. 2376-2385

DOI: 10.1056/nejmoa1801109

Field-Weighted Citation Impact: 12.48